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Health Care Reform's Proposed
End-of-Life Provisions
Brandy C. Hill, JD, Nick Lebredo, CPA, MBA, Christopher R. Shafer, MBA
ABSTRACT
End-of-life planning promotes patient autonomy by allowing individual patients to inform and direct care givers and
healthcare proxies on their desired level of end-of-life care, where the patient prefers to pass away (whether at home or in
a hospital setting), and the methods and levels of pain management that the patient deems desirable. Given that, it is
counter-intuitive that a significant majority of American's fail to execute, or fail to properly execute, advance directives.
The author’s efforts focus on what can be done to improve, generally, end-of-life care. To that end, the authors conclude
that improvements in end-of-life care must be achieved at three levels: the individual level, the healthcare provider level,
and at the government level. On the individual level, patients must assume greater accountability for their own end-of-life
care. That entails making one's wishes for end-of-life care known to family members and healthcare providers. On the
healthcare provider level, improved patient communication and improved delivery of palliative-oriented care are first
order initiatives. Finally, the government can play a significant role in improving end-of-life care by collecting better
healthcare utilization and cost data on end-of-life experiences, expanding benefits for palliative care services, and
promoting the use of advance directives through legislative efforts that include patient education measures.
Florida Public Health Review, 2010; 7, 50-63.
Background
Perhaps at no point in this country’s recent
history has a debate fueled emotions within the halls
of Congress, and within the citizenry, more than
healthcare reform. Much of the debate during the
2009 healthcare reform effort, arguably President
Barack Obama's biggest domestic policy initiative
during his first year in office, has been rife with
hyperbole; politicians have charged that reform of the
American healthcare system will result in the creation
of “death panels” that will “pull the plug on
grandma” or otherwise coerce people to “die quickly”
(Palin, 2009; Grayson. 2009). Consequently, end-oflife considerations, mired with the complexities of
patient autonomy, costs, and ethics, have been highly
visible in the current healthcare reform debate.
As a result of advancements in medicine and
medical technology, individuals in the United States
are living longer lives. Although these advances
continue to increase life expectancy, attention to the
quality of life and to the inevitable experience of
dying, has not kept pace (Grady, 1999). With
increasing life expectancies come increasing
healthcare costs. To that end, there are three central
concerns regarding end-of-life healthcare policy
reform. Those are: (1) the use of advance directives
and other measures that serve to increase patient
autonomy; (2) the benefits of hospice care to improve
the quality of care received at end-of life and avoid
unnecessary costs associated with futile medical
treatments at end-of-life; and, (3) the use of pain
Florida Public Health Review, 2010; 7:50-63.
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management at end-of-life and the delicate balance
between patient autonomy and ethical medical
treatment that must be achieved in connection
therewith (Werth & Blevens, 2002).
At the outset, it is important to establish the
parameters of what constitutes end-of-life. For
purposes hereof, the National Institutes of Health
definition is adopted. The term end-of-life can take
on various meanings, and none are definitive.
According to The National Institutes of Health, there
are two constituent parts to end-of-life. The first is
the presence of one or more chronic diseases,
symptoms, or functional impairments that may persist
or fluctuate. The second is the presence of symptoms
or impairments resulting from an underlying,
irreversible disease, requiring formal (paid,
professional) or informal (unpaid, unskilled) care,
and can lead to death (Heitkemper, Bruner, et al.,
2004). End-of-life can also be defined by advanced
age. However, with advanced age there are generally
indicia of “debility, dementia, and protracted chronic
and terminal illnesses” (Hardwig, 2009).
Individuals at end-of-life may face legal
incapacity and rendering them incapable of
expressing their wishes, with regard to end-of-life
healthcare. This very point was evidenced in the Terri
Schiavo case. Recall that Ms. Schiavo was in a
persistent vegetative state and a fierce legal battle
ensued between her parents and husband regarding
who had the right, if anyone, to order her life support
withdrawn. That legal battle played out in the
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national news media in early 2005. The case
ultimately ended with her various life support
treatments being removed, and Ms. Schiavo passing
away shortly thereafter. The case offered a valuable
lesson in advance directives, and their vital
importance within society.
The majority of Americans fail to adequately
plan for end-of-life. As a result, many are illprepared for end-of life and/or otherwise uneducated
about available end-of-life planning tools. On the
individual level, the risk of failing to plan for end-oflife is the possibility of being unable, because of legal
or physical incapacity, to relay one’s desired end-oflife healthcare wishes. On the societal level, the
implications of failing to adequately plan for end-oflife can result in legal battles regarding healthcare
decisions, and needless escalation of healthcare costs.
“We do not have a [end-of-life] game plan as a
society” (Gari, 2009). This proposition is a risky one.
Though a controversial issue that touches upon
medicine, law, ethics, religion, politics, common
sense, and extremism, giving a patient the right to
determine the manner in which he or she handles
end-of-life (including the right to die) is a powerful
directive that individuals and their families feel
should be within their control (Haras, 2008; Caplan,
McCartney, & Sisti, 2007). Further to that
commonly-held sentiment, it becomes apparent that
understanding and using advance planning directives
is essential. Advance directives, including living
wills, healthcare proxies, do-not-resuscitate (DNR)
orders, and healthcare powers of attorney, are legal
documents governed by state law that express an
individual's choice of surrogate healthcare decisionmaker and/or an individual's treatment preferences in
the event of incapacity (Kohn & Blumenthal, 2008;
Darr, 1999). Even though the importance of advance
directives is high, it is estimated that the use of
advance directives is relatively low—between 16%
and 27% (Cohen-Mansfield & Lipson, 2008; Ho,
Thiel, Rubin, & Singer, 2000; Rosnick & Reynolds,
2003; Wallace, Weiner, Pekmezaris, Almendral,
Cosiquien, Auerbach, & Wolf-Klein, 2007). Most
significantly, for purposes of the instant discussion,
advance directives generally provide instruction as to
whether the maker wishes to receive or decline
artificial life-sustaining treatments at end-of-life.
Advance directives may serve a financial
purpose, aiding in healthcare cost containment. This
is a commonsense conclusion. If an individual is
willing to forgo costly measures to artificially sustain
life and/or other heroic end-of-life treatment options,
we assume that there will be a resulting net reduction
in the cost of end-of-life treatment provided to that
individual (Nishimura, 2007). There is research that
substantiates this assumption, while other research
Florida Public Health Review, 2010; 7:50-63.
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has been inconclusive (Mezey & Ramsey, 1994).
Irrespective of the cost containment issue, it is
important not to lose sight of the reason advance
directive laws exist. That is, to carry out the
intentions and wishes of the person making the
advance directive in the event of his or her
incapacity.
Patient Autonomy: Legislative Attempts at Endof-Life Planning Mandates
America's Affordable Health Choices Act
In any end-of-life discussion, a complex set of
policy issues, economic issues, and legal issues is
expected to emerge. Weighty ethical concerns are
adjunctive thereto. Public debate of end-of-life
issues abounded following the introduction, in midJuly 2009, of the America's Affordable Health
Choice Act (H.R. 3200). H.R. 3200 was politicized
for the reason that the proposed legislation contains a
provision for advance care planning consultations in
Section 1233 thereof (H.R. 3200 § 1233). Such
advance care consultations—proposed to take place
on a voluntary basis every five years between a
patient, namely, a Medicare or Medicaid recipient,
and his or her healthcare practitioner—include
explanation, by the healthcare practitioner, of
advance directives and the continuum of end-of-life
services, including palliative care and hospice care.
One of the more controversial provisions within H.R.
3200 § 1233 includes providing patients with “an
explanation of orders regarding life sustaining
treatment or similar orders … [and] the reasons why
the development of such an order is beneficial to the
individual and the individual's family.” Impliedly
contained within H.R. 3200 § 1233 is the dictum that
executing an advance directive is beneficial for the
reason that it ensures that the individual's wishes
regarding end-of-life care will be carried out, in the
event that the individual becomes incapacitated and
unable to make his or her own healthcare decisions.
H.R. 3200, the proposed legislation responsible
for the timeliness of this discussion, comprises a
significant piece of proposed legislation in the 2009
healthcare reform initiative, but it is by no means the
only proposed legislation germane to that effort.
H.R. 3200 is the product of three U.S. House
Committees, namely, the House Energy and
Commerce Committee; the House Ways and Means
Committee; and the House Education and Labor
Committee. Collectively, these committees, with
regard to H.R. 3200, are sometimes called the “TriCommittee.” There are additionally two pieces of
proposed legislation relating to the 2009 healthcare
reform initiative introduced in the U.S. Senate.
Those are America's Healthy Future Act of 2009 (S.
1796) introduced in the Senate Finance Committee
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and the Affordable Health Choices Act (S. 1679).
Significantly, neither Senate bill includes language
similar to H.R. 3200 § 1233 or otherwise provides for
advance care planning consultations.
H.R. 3200 § 1233, has been attacked on the basis
that it is, according to its opponents, intended to
dissuade certain persons from consuming certain endof-life healthcare treatments–charging, essentially,
that there is potential for abusive and/or disparate
application. In particular, H.R. 3200 § 1233 is limited
to Medicare and/or Medicaid recipients and,
accordingly, it is those persons who would receive
the voluntary (or, voluntary but for the “white coat”
influence) advance care planning consultations
provided for therein. It is proposed that those
consultations occur at five-year intervals or “more
frequently … if there is a significant change in the
health condition of the individual, including
diagnosis of a chronic, progressive, life-limiting
disease, a life-threatening or terminal diagnosis, or
upon admission to a skilled nursing facility” (H.R.
3200 § 1233). There can be little argument that
aforementioned group (Medicare and/or Medicaid
recipients) is comprised largely of the elderly, the
terminally-ill, or other groups which may be at or
near the end-of-life stage. By reimbursing physicians
for time spent counseling patients who experience “a
significant change in … health condition” a straightfaced argument can be made that § 1233 promotes
the use of advance directives as a means of cost
containment and/or healthcare rationing. Further, that
cost containment or healthcare rationing would come
at the cost of disproportionately providing less
available healthcare services and measures, to
Medicare and/or Medicaid recipients. This, though,
may be an incurable inequity inasmuch as some
research suggests that physicians treating patients
whose care is covered by government-funded
insurance (namely, Medicare and Medicaid) are more
likely to issue a DNR order, or otherwise forgo
heroic end-of-life treatment options, than they are for
patients covered by private insurance (Nordquist,
2006).
Proponents of H.R. 3200 § 1233 advocate the
position that advance care planning consultations
necessarily involve only cognitive and legally
competent persons. Furthermore, in connection with
providing an advance care planning consultation
under § 1233, a healthcare practitioner is required to
advise the patient of the substantial legal safeguards
available. This would further protect the individual
against the risk of an appointed surrogate healthcare
decision-maker terminating life-sustaining measures
based on the surrogate's judgment, morals and/or
values (H.R. 3200). Those favoring legislation which
encourages advance care planning argue that such
Florida Public Health Review, 2010; 7:50-63.
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“measure[s] would not only help people make the
best decisions for themselves, but also ensure that
their wishes are followed. To suggest otherwise is a
gross, even cruel, distortion, especially for a family
that has been forced to make the difficult decisions
on care for loved ones approaching the end of their
lives” (Blumenauer, 2009). The cost containment
argument cannot be ignored here. Proponents of
legislative efforts to encourage the use of advance
directives also maintain that the outcome will be the
alleviation of exorbitant federal spending on costs
incurred, arguably, largely in connection with futile
efforts to unnaturally extend the life of an individual
(Schneider & Hall, 2009).
Further substantive discussion of by H.R. 3200
§ 1233—which may be somewhat cumulative in light
of the Patient Self-Determination Act, infra—is not
ripe as it has not as of the time of this writing, and
perhaps may not, mature into enacted federal
legislation. However, the proposed legislation did, as
previously mentioned, serve to bring the end-of-life
planning issue to the forefront of the American
conscious. It also served to bring to light the
question of whether federal legislative efforts can
increase the use of end-of-life planning instruments
such as advance directives. Analysis of other enacted
federal and state legislation is both germane and
instructive in the end-of-life planning discussion at
this juncture. In particular, the Patient SelfDetermination Act is examined herein relative
encouraging end-of-life planning in furtherance of
patient autonomy. Additionally, the Oregon Death
with Dignity Act and the Washington Death with
Dignity Act, which authorize physician-assisted
suicide in limited circumstances in those states, are
examined relative to their policy implications relative
to patient autonomy at end-of-life. The concomitant
economic effects of those legislative initiatives are
also addressed.
Patient Self-Determination Act
The Patient Self-Determination Act (42. U.S.C.
§§ 1381, et seq.) (hereinafter the “PSDA”), enacted
in 1991, made it a federally legislated requirement
that individuals treated in institutions receiving
Medicare and/or Medicaid reimbursements be asked
about the presence or the absence of an executed
advance directive regarding that individual's express
wishes for potential end-of-life care (42 U.S.C. §
1395). The legislative purpose behind the PSDA was
to increase the use of advance directives regarding
end-of-life treatment decisions (O'Rourke, 2000). In
relation to H.R. 3200 § 1233, the language of the
PSDA is notably less value-laden. The specific
language of the PSDA provides that “each hospital
nursing facility, provider of home healthcare or
personal care services, hospice program, or health
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maintenance organization…receiving funds under
[Medicaid and/or Medicare] shall…provide written
information…concerning an individual's right under
State law (whether statutory or recognized by the
court of the State) to make decisions concerning such
medical care, including the right to accept or refuse
medical or surgical treatment and the right to
formulate advance directives…[and] to document in
the individual's medical record whether or not the
individual has executed an advance directive” (42
U.S.C. § 1395 cc (a)). The PSDA does not require the
healthcare provider to determine the legal sufficiency
of the advance directive or obtain a copy thereof
(Mezey & Ramsey, 1994). By presenting an
individual's right to execute an advance directive as
an individual choice to accept or refuse certain lifesustaining treatments, the PSDA is significantly more
value-neutral than H.R. 3200 § 1233. Also, under the
PSDA, a covered institution may not make the
provision of care conditional upon whether the
individual has or has not executed an advance
directive, to do so is considered discriminatory under
the Act (Mezey & Ramsey, 1994; 42 U.S.C. § 1395cc
(a)(2)(C)). H.R. 3200 provides reimbursements to
physicians for time spent conducting advance care
planning consultations held, in part, for the purpose
of explaining to the individual “the reasons why the
development of such an order is beneficial to the
individual and the individual's family” (H.R. 3200 §
1233). There is no explanation in H.R. 3200 as to
how the proposed legislation presumes advance
directives to be beneficial. One view is that they are
beneficial for the reason that they are designed to
instruct family and/or healthcare provider, on how an
individual may desire to carry out end-of-life
treatment. A more cynical view is that forgoing
certain end-of-life treatments result in less federal
healthcare spending.
One major difference between H.R. 3200 § 1233
and the PSDA regarding advance directives is that
H.R. 3200 § 1233 proposes to educate individuals on
advance directives. There is not a similar education
component in the PSDA. Accordingly, to the extent
that later federal legislation may provide for patient
education regarding advance directives, the same
would not be wholly cumulative in light of the
PSDA. It is significant to note that research suggests
that advance care planning education (in the nature of
that proposed by H.R. 3200 § 1233) may increase the
rate at which advance directives are executed, but
that the resulting executed advance directives may
fall short of the legal requirements set forth by state
law to make them sufficient, valid and/or enforceable
(Ho, et al., 2000; Aroskar, Moldow, & Good, 2004).
Therefore, a critical failure of any law enacted for the
purpose of increasing the use of advance directives,
Florida Public Health Review, 2010; 7:50-63.
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that does not require a determination as to whether or
not an individual has a valid and legally enforceable
advance directive, is that a significant number of
individuals may believe that they have an advance
directive, and may report that fact to their healthcare
provider, when, in fact, they have executed a
document which cannot later be given effect. Neither
the PSDA nor the proposed H.R. 3200 requires that
the legal sufficiency of an individual's advance
directive be determined.
It is suggested that that legislative efforts can
positively influence the rate at which individuals
execute advance directives to express their wishes for
end-of-life, which conforms to the legislative purpose
of the PSDA. Accordingly, the ability of legislation
to change patterns of end-of-life care consumption
and the ability of legislation to promote the use of
advance directives is a potent consideration. To that
end, it is suggested that further research is needed to
determine whether narrowly tailored legislation,
which includes a patient education component and a
means for determining the legal sufficiency of
advance directives, is likely to positively impact
patient autonomy at end of life.
The Right to Die
The right to die may be the ultimate measure of
patient autonomy. When considering various end-oflife options for terminally ill patients, it must be
considered whether physician-assisted suicide is a
viable one. Oregon became the first state in the
United States to permit physician-assisted suicide in
1997. Eleven years later, Washington state, became
the second (Campbell, 2008; Jecker, 2009).
The Oregon Death with Dignity Act (Or. Rev.
Stat. Ch. 127, hereinafter the “Oregon DWDA”) and
the Washington State's Death with Dignity Act (Rev.
Code of Wash. §§ 70.245.010, et seq., hereinafter the
“Washington DWDA”) are measures of patient
autonomy inasmuch as they provide a legal right for
physician-assisted suicide in certain limited
circumstances. The Oregon DWDA sets forth
detailed requirements and procedures by which a
mentally competent but terminally ill adult resident
of Oregon may voluntarily “make a written request
for medication for the purpose of ending his or her
life in a dignified manner” (Or. Rev. Stat.
§127.805(1)). The patient must be suffering from “an
incurable and irreversible disease that has been
medically confirmed and will, within reasonable
medical judgment, produce death within six months”
(Or. Rev. Stat. § 127.800(12)). The patient's written
request must be signed and dated in the presence of at
least two witnesses who attest that the patient is
“competent and acting voluntarily” (Or. Rev. Stat. §
127.810(1)). The Washington DWDA, modeled after
the Oregon statute, contains substantially similar
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limitations on its application. The Oregon DWDA
was enacted primarily to “expand patient control over
end-of-life choices” (Campbell, 2008). Between 1998
and 2008, 401 individuals ended their lives under the
Oregon DWDA (Oregon Department of Human
Services). In 1998, 97% of those individuals died at
home, whereas 98% had some form of hospice care.
The primary reason, as stated by 95% of those
terminally-ill individuals choosing to end their lives
under the Oregon DWDA, was loss of autonomy.
Accordingly, there appears to be a compelling policy
argument in favor of laws such as the Oregon DWDA
and the Washington DWDA in furtherance of patient
autonomy.
Prior to enactment of the Oregon DWDA, the
state of the law regarding physician-assisted suicide
was shaped by two United States Supreme Court
decisions rendered in 1997. In the first seminal case,
Washington v. Glucksberg, 521 U.S. 702 (1997), the
Supreme Court held that a Washington state law
banning physician-assisted suicide was constitutional
and, accordingly, an individual, even a terminally-ill
individual, has no constitutionally protected right to
die by means of intervention provided by a licensed
medical physician (i.e., physician-assisted suicide).
Specifically, the Supreme Court held that
“[t]hroughout the Nation, Americans are engaged in
an earnest and profound debate about the morality,
legality, and practicality of physician-assisted
suicide. Our holding permits this debate to continue,
as it should in a democratic society” Glucksberg, 521
U.S. at 737. This holding suggests that states have the
right to enact legislation permitting physicianassisted suicide in limited instances. The second
contemporaneously issued Supreme Court ruling,
rendered in Vacco v. Quill, 521 U.S. 793 (1997) held,
similarly, that a New York state law that banned
physician-assisted suicide in that state was
constitutional. The Vacco Court decided that states
could ban physician-assisted suicide but it was silent
as to whether a state could affirmatively authorize the
same.
Glucksberg and Vacco seemingly opened the
door for state legislation permitting physicianassisted suicide in limited instances where the
“proper balance between the interests of terminally
ill, mentally competent individuals who seek to end
their suffering and the State's interests in protecting
those who might seek to end life mistakenly or under
pressure” could be achieved (Glucksberg, 521 U.S.
At 737). Nonetheless, the Oregon DWDA faced
significant legal challenges following its enactment.
Those challenges were based primarily on the federal
Controlled Substances Act (21 U.S.C. §§ 801, et seq.,
hereinafter the CSA). The CSA is a federal law that
regulates the legal and illicit manufacture,
Florida Public Health Review, 2010; 7:50-63.
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distribution, and possession of controlled substances.
Oregon physicians who sought to assist terminally-ill
patients in ending their lives in conformity with the
Oregon DWDA, were threatened with federal
prosecution for violation of the CSA, by reason of a
2001 interpretive rule issued by the U.S. Attorney
General (John Ashcroft, at that time) which opined
“assisting suicide is not a 'legitimate medical purpose'
within the meaning of 21 C.F.R. § 1306.04 (2001),
and that prescribing, dispensing, or administering
federally controlled substances to assist suicide
violates the CSA. Such conduct by a physician
registered to dispense controlled substances may
'render his registration...inconsistent with the public
interest' and therefore subject to possible suspension
or revocation under 21 U.S.C. § 824(a)(4). This
conclusion applies regardless of whether state law
authorizes or permits such conduct by practitioners or
others and regardless of the condition of the person
whose suicide is assisted.” This interpretative rule
came to be known as the Ashcroft Directive (Hilliard,
2005). Accordingly, under the Ashcroft Directive,
any physician who prescribed a lethal dose of a
controlled substance to a terminally-ill patient would
be subject to federal criminal prosecution.
The United States Supreme Court ultimately
resolved that the Attorney General was not
authorized to issue an interpretive rule limiting the
right of the State of Oregon to legislate medically
appropriate uses of drugs not otherwise prohibited
under the CSA—that matter is reserved to the states.
Gonzales v. Oregon, 546 U.S. 243 (2006). To that
end, physician-assisted suicide in the limited manner
provided by the Oregon DWDA is specifically
sanctioned and similar legislation may be enacted by
the various states.
Whereas patient autonomy is a paramount
concern at end-of-life, and in healthcare policy more
generally, the matter of physician-assisted suicide is
not appropriate for national policy. The “challenging
task of crafting appropriate procedures for
safeguarding…liberty interests is entrusted to the
'laboratory' of the States” (Glucksberg, 521 U.S. at
737).
Hospice Care
It should come as no surprise that medical costs
tend to increase with age, with the peak spending rate
coming at the final stages of life. The Kaiser Family
Foundation,
a
leader
in
health
policy
communications, conducted a study in 2006,
highlighting the enormous increase in healthcare
spending at end-of-life. The Kaiser Family
Foundation study examined six age groups: newborn
to age 5; age 5 through 17; age 18 through 24; age 25
through 44; age 45 through 64; and 65 years of age
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and older. The latter group, which is Medicareeligible and which accounts for 70% of all deaths in
the United States annually, consumed, on average,
$8,776 in federal healthcare dollars per person in
2006 (Grady, 2009; Adamy, 2009). This figure is
almost $4,000 more than the next highest spending
age group: those between the ages of 25-44. The
findings reported by the Kaiser Family Foundation
support the argument that there is extraordinary
spending in the final stages of life. The study also
raises questions, with regard to whether Americans
are being over-treated at end-of-life. The U.S.
healthcare system offers multifarious treatment
options during an individual's end-of-life period.
However, many seeking care often go directly to the
hospital, regardless of their signs or symptoms. This
often drives up unnecessary costs and further
increases pressure on curbing medical spending
during end-of-life. Many are unaware of other endof-life care options that can provide an appropriate
level of care, at a more modest cost. A survey
conducted with the input of 2,515 Medicare patients
found that 86% of those surveyed would rather spend
the last days of their lives at home, rather than in a
hospital. However, 80% of Americans die in
institutions, mainly hospitals or nursing homes (Jaffe,
2009).
With Baby Boomers entering retirement age,
Medicare, Medicaid, and Social Security spending
are on the rise in the United States. As of 2008 there
were over 45.3 million Medicare beneficiaries
(Overview Medicare Enrollment Reports, 2008)
consuming $468 billion in healthcare services
annually. This number amounts to 3.2% of the
nation's total Gross Domestic Product (GDP), and
that figure is projected to balloon to 11.4% over the
next 70 years (Medicare Trustees Report & Trust
Funds, 2009). By that estimate, Medicare spending
will reach $931.9 billion by 2019—essentially
doubling in the next 10 years (Jaffe, 2009). Medicare
spending is not distributed evenly over all
beneficiaries. From 1995-1999, 5% of Medicare
beneficiaries accounted for some 47% of total
Medicare spending (Lieberman, Lee, Anderson &
Crippen, 2003). As a result, end-of-life (and, more
particularly, end-of-life healthcare spending) has
become a hot button topic in American politics and
policy. Because Medicare commands such a presence
in the overall federal budget, cost containment in
high spending areas has become a focal point. So the
following question arises: How do we as a society
cut costs, while at the same time, provide high quality
healthcare to those in end-of-life scenarios? “In some
[potentially end-of-life] cases hospital care is
essential, especially for those experiencing trauma,
cardiovascular, cerebrovascular, among other
Florida Public Health Review, 2010; 7:50-63.
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emergent events.” (Ortiz-Rios, 2009) In other cases,
however, individuals could receive the appropriate
level of end-of-life care in the home, or in a hospice
environment. When individuals choose to spend their
final days in hospitals, they are choosing a costly
option. By way of example, an individual 65 years or
older, suffering from pancreatic and/or liver cancer,
seeking care in a Florida hospital, can expect to
spend from $18,017 to $49,050 for a 6-day hospital
stay (FloridaHealthFinder.gov, 2008). The average
of that range is $33,533. Many individuals turn to
hospital care because that is the assumed choice.
There is also a sense of comfort for patients knowing
that they have a doctor or nurse in close proximity,
no matter what time of the day it may be.
Hospice care, though, offers a variety of end-oflife treatment and care options for patients and their
families, including in-home care, inpatient facilities
(Hospice Houses), and around-the-clock nursing care.
Hospice care is an ever-growing popular option for
end-of-life care. In 2007, Hospice served 1.4 million
patients, which is a 450,000-patient increase from
2003 (NHPCO Facts and Figures, 2008). Hospice
was also involved in 38.8% of all deaths occurring in
the United States in the year of 2007 (NHPCO Facts
and Figures, 2008). It is a benefit that is covered by
Medicare, and has been since 1982. Significantly,
hospice care is often less costly than hospital care. In
a typical hospice scenario, a family member serves as
the primary care giver for the patient, with hospice
healthcare providers being available 24 hours a day.
An interdisciplinary team of healthcare providers
works with family members to create an explicit care
plan for the terminally ill individual. Hospice often
reduces cost while, at the same time, improves the
quality of end-of-life care over that which would be
received in a hospital or institutional setting. A study
conducted by Duke University researchers,
concluded that hospice saves the Medicare program
around $2,300 per beneficiary when the beneficiary
expires in hospice care. The maximum cumulative
savings noted by the study were as high as $7,000
when beneficiaries with terminal illnesses used
hospice for 58–103 days prior to their death (Taylor,
Ostermann, Van Houtven, Tulsky & Steinhauser,
2007).
Similar to hospice care, is the option for private
in-home care, which enables a patient and their
families more control in what type of care is
provided. Many commercial insurance plans, as well
as Medicare, offer an in-home care benefit, allowing
various healthcare providers to engage patients in the
comfort of their own homes at end-of-life (ACHC;
Maxim Healthcare Services, 2009). In-home care can
include around-the-clock nursing, nursing aide, or
physical therapy care, resulting in considerable cost
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savings when compared to hospital or institutional
care. Skilled providers, such as registered nurses
providing in-home care, are compensated at about
$10 less per hour, than facility nurses. Similarly,
unskilled providers, such as nursing aides or home
health aides, are compensated at a rate of about $5
less per hour than facility unskilled providers. For
end-of-life patients serving out their final days, “there
is nothing that can’t be done at the home” (Gari,
2009).
Pain Management
Pain management is a dicey subject for some
healthcare professionals. It is fraught with moral and
ethical concerns. There is not a “one size fits all”
handbook for pain management medication at end-oflife. Healthcare providers have to use sound
judgment and education to determine the appropriate
level of medication(s) to administer. A
comprehensive pain assessment is required both to
choose initial therapy and to measure its effectiveness
(Abrahm, 1998). Generally, the severity of the
patient’s symptoms will determine the amount of the
drug given by the healthcare provider to the patient.
The ethical concern from a provider standpoint arises
most commonly when the patient is unable to
verbally indicate their pain level, and the provider is
forced to make a determination about appropriate
types and amounts of medications.
End-of-life can often be accompanied by severe
pain and other unpleasant symptoms that cause undue
suffering (ASPMN, 2003). Turning to pain
management or palliative care techniques, can be a
cost effective health option that may improve the
quality of life (and the dying experience) for
terminally ill individuals. Palliative care is defined by
the World Health Organization as “improving the
quality of life of patients and families who face lifethreatening illness, by providing pain and symptom
relief, spiritual and psychosocial support to, from
diagnosis to the end of life and bereavement (WHOPalliative Care, 2009).” Pain management procedures
can be administered in an office setting, an outpatient
ambulatory surgery facility, hospital, and/or in-home
care. Regardless of the setting, however, healthcare
providers often times have to walk a fine ethical line,
between what is appropriate amount of medication
for comfort, and what can be detrimental to the
patient.
For a patient that has mild pain and suffering, the
provider may choose to give a lower strength
medication such as an over-the-counter analgesic.
However, if the patient’s pain goes into the moderate
category, a controlled substance such as oxycodone
may be given. Severe pain levels for those suffering
end-of-life illnesses are often treated by highly potent
Florida Public Health Review, 2010; 7:50-63.
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drugs, such as morphine, to allay pain symptoms.
Drugs like morphine, if given in an accidentally
overdosed quantity, can weaken a patient's pulse,
shallow breathing, cause fainting, halt breathing, and
can cause death at certain dosage levels (Morphine
Information, 2009). There can be a wide range from
the initial dosage given to a patient, to the maximum
recommended
dose
(Ortiz-Rios,
2009).
Proportionate palliative sedation is the practice of
administering the lowest dose of pain management
therapy to achieve comfort for the patient.
Proportionate palliative sedation is widely accepted
as an ethical medical practice (Quill, 2009). Contrast
proportionate palliative sedation with palliative
sedation to unconsciousness, a pain management
therapy whereby unconsciousness is the intended
effect to achieve maximum pain relief for the patient.
The patient is then left in an unconscious state
generally without artificial nutrition or hydration
until the patient dies (Quill, 2009). The practice has
been condoned by the United States Supreme Court
in Glucksberg, supra, wherein the Court held that
“[a] patient who is suffering from a terminal illness
and who is experiencing great pain has no legal
barriers to obtaining medication from qualified
physicians, even to the point of causing
unconsciousness and hastening death” However, the
practice is considered controversial within the
medical community and should not be used as a back
door means of carrying out physician-assisted suicide
(Quill, 2009).
Whereas pain management may be controversial
in nature, it is important to not overlook its important
role in the end-of-life discussion. When taking into
account all the end-of-life aspects conferred herein,
pain management can offer a sense of autonomy and
comfort to a patient, while being a cost efficient
health choice. With the extensive choices, both in
treatment options and environments in which services
can be rendered, pain management should be a
meaningful option for anyone seeking or planning
end-of-life care.
Historical Policy Analysis – Lessons from the Past
Healthcare policy reform recommendations, as
previously mentioned and discussed, have largely
been focused in three key areas with regard to end-oflife: “(a) advance directives; (b) hospice benefit; and
(c) pain management” (Werth & Blevens, 2002, p.
406).
Further to those recommendations, it is germane
to examine outcomes of the PSDA to determine the
extent to which legislative efforts can promote the
use of advance directives. In a report completed
nearly five years after the enactment of the PSDA,
the General Accounting Office (GAO) indicated that
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a significant majority of covered healthcare
institutions were complying with most of the
provisions of that legislation (GAO, 1995). The GAO
report, however, expressed concern about the
“effectiveness” of the legislation. Two of the major
challenges to the efficacy of the PSDA identified in
the aforementioned GOA report included: (1) the
persistent low level of participation among people
actually choosing to exercise the right to execute an
advance directive and (2) the lack of thorough
discussion between patient and healthcare provider
regarding treatments that may be carried out pursuant
to an advance directive for those individuals with
completed advance directives (GAO, 1995).
According to the GAO, a counseling session was
deemed critical to ensure that the patient was fully
aware of the implications of their decisions, as well
as to ensure that the healthcare provider fully
understood the patient’s wishes (GAO, 1995).
According to several empirical studies, advance
directive planning expectations have fallen short of
the initial promise of the PSDA legislation
(Prendergast, 2001).
With respect to hospice services, the Tax Equity
and Fiscal Responsibility Act of 1982 (42 U.S.C. §
1395, et seq.), which expanded coverage for hospice
care for qualified Medicare beneficiaries, was a
significant legislative accomplishment (Blevins &
Deason-Howell, 2002). However, making an accurate
prognosis of the point in time that marks end-of-life
(and, coincidentally, the start of Medicare benefits for
hospice care) remains a substantial challenge (Werth
& Blevens, 2002). Notwithstanding the significant
advances in medicine, predicting death with a high
degree of certainty remains extremely difficult
(Scitovsky, 2005). As a result, there are wide
variations in treatment periods, quality of care, and
cost associated with hospice care on a patient-topatient basis. Improving our understanding of the
causes of these variations could be enormously
beneficial to benchmarking performance and
standardizing best practices (White, Cochran, &
Patel, 2002).
Efforts to improve pain management at end-oflife center primarily around three key issues: (1)
managing the cost for effective pain management,
which can be expensive and sometimes not covered
by Medicare; (2) improving physician education
about pain management; and, (3) dealing with
regulatory barriers that may restrict a physician from
prescribing certain aggressive pain management
regimens (Werth & Blevens, 2002). Recent federal
legislation initiatives related to end-of-life pain
management have not seen much, if any, real success.
The most recent, the Conquering Pain Act of 2005
(S.B. 999), which proposed to establish “evidenceFlorida Public Health Review, 2010; 7:50-63.
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based practice guidelines for pain treatment”,
experienced a fate similar to its predecessors by
failing to emerge from committee referral (S.B. 999).
However, it has become more and more clear to the
medical community that the importance of effective
pain management during end-of-life cannot be
understated. “To restore a balance between a
physician's obligation to prolong life and obligation
to relieve suffering, a peaceful death must be
acknowledged as a legitimate goal of medicine and as
an integral part of a physician's responsibilities”
(Meier, Morrison, & Cassel, 1997, pg. 226).
Imminent Crisis or Opportunity for Incremental
Reform
Whereas end-of-life concerns are certainly not
confined to the elderly, it is important to note that
approximately two-thirds of the people that die in the
United States each year are the elderly, i.e., 65 or
older (Scitovsky, 2005). This is significant because
Medicare studies provide some of the best
information on end-of-life costs (Scitovsky, 2005).
Conceding the limitations of this data source, we can
still glean valuable insights on end-of-life costs from
its consideration.
Approximately one-fourth of Medicare spending
is attributable to individuals in their final year of life
(Buntin & Huskamp, 2002). At least one study has
reported that Medicare beneficiaries in their final
year of life spend nearly six times as much as other
Medicare beneficiaries (Hogan, Lunney, Gabel, &
Lynn, 2001). Whereas on the surface this seems to
suggest an imminent crisis with end-of-life costs,
further research on the issue suggests otherwise.
Of particular interest is the observation that the
percentage of Medicare costs due to end-of-life care
has remained relatively consistent over the last two
decades (Hogan, et al., 2001). This same study
concluded that end-of- life costs do not appear to be a
leading cause of the growth in healthcare spending
(Hogan, et al., 2001). In fact, the stability of this
trend may suggest that higher end-of-life costs are
largely inevitable and, consequently, there is little
that can be effectively done to reduce the need for
higher levels of end-of-life healthcare spending,
particularly when related to acute care (Liu, Wiener,
& Niefeld, 2006). Some researchers suggest that the
higher cost of end-of-life care may be primarily
associated with treating severe illness and functional
impairment, rather than exceptional or extraordinary
circumstances associated with being near the end-oflife (Hogan, et al., 2001). Further to this hypothesis,
multiple studies have concluded that the healthcare
costs of decedents and survivors suffering from
similar illnesses are comparable (Liu, et al., 2006).

57
8

Hill et al.: Health Care Reform's Proposed End-of-Life Provisions

These studies suggest that seeking ways to reduce
end-of-life healthcare costs, while highly worthy of
consideration, may not be the panacea that some
reform advocates suggest to controlling the high
growth of national healthcare spending. With respect
to end-of-life care, there are certainly many prospects
for incremental reform. Some of these opportunities
will be explored below. Maintaining reform
expectations within the realm of actionable and
realistic is imperative. As Scitovksy (2005)
concludes, “the data from studies conducted to date
do not provide a basis for a policy of singling out one
group of patients for cost-containment strategies” (p.
837).
Perception vs. Reality
The ensuing controversy associated with the endof-life counseling provision in H.R. 3200 § 1233
prompts us to consider additional questions. What do
we really know about cost inefficiencies that exist
with respect to end-of-life care or the quality of endof-life care? Can we significantly reduce healthcare
spending by reducing end-of-life healthcare costs
without sacrificing quality of care? A common
perception is that there are widespread cost
inefficiencies and unnecessary provisions of
healthcare during the end-of-life. While it is clear that
inefficiencies do exist, the potential cost savings from
end-of-life care reforms are not as certain. A recently
completed study by the Urban Institute, a public
policy research organization, indicated that while
there were opportunities for cost savings, most of
healthcare spending at the end-of-life was
unavoidable (Urban Institute, 2009). This same report
suggested that many analyses that target the “high
cost of dying” inappropriately disregard similarly
sick survivors that receive comparable care and
benefited from the high cost treatments (Urban
Institute, 2009).
In a 2009 report, “How Can We Pay for
Healthcare Reform,” the Urban Institute identified
over $1.3 trillion in possible cost savings over a ten
year period. Of this amount, the cost savings
attributable to end-of-life healthcare reform was
about $91 billion over the ten-year period from 20102019 (Urban Institute, 2009). Clearly, this estimated
level of potential healthcare savings is not trivial.
Yet, it accounts for only approximately seven percent
(7%) of the total estimated cost savings identified in
the report. Most of the end-of-life cost savings
estimate in the Urban Institute’s 2009 study was
attributable to reducing Medicare beneficiary related
costs by 1.25% per year (Urban Institute, 2009).
Accordingly, while the potential for end-of-life
related cost savings does exist, it is prudent to
moderate expectations with respect to the attainable
impact that may have on healthcare reform.
Florida Public Health Review, 2010; 7:50-63.
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What can we state about the potential for
improving the quality of end-of-life care? The
common perception and, in some respects, common
fear, regarding this issue may be that greater
consideration of palliative care will likely involve
decisions leading to less quality of care. While the
results of much of the earlier qualitative research
were mixed, relatively recent quantitative research
appears to indicate that palliative care particularly
when it is possible to provide at home provided the
highest quality of care satisfaction from the
perspective of family members (Teno, Clarridge,
Casey, et al., 2004; Higginson, Finlay, Goodwin, et
al., 2003). Notwithstanding the recent research, the
possible benefits of palliative care are not fully
understood. Unfortunately, many still fear that
palliative care means the end of care.
Actionable Initiatives
What can be done to improve the provision of
end-of-life care? Is it realistic to expect quality
improvements while pursuing cost efficiencies?
Discussed below are key initiatives that individuals,
healthcare providers, and the government may
consider to potentially improve end-of-life care.
Individual Action
As individuals, and as a society, we would
benefit by becoming more comfortable with death.
This seems too obvious to even mention. Death is a
certainty for all of us. However, for too many of us,
death is still a subject we avoid discussing even with
our closest loved ones. It is difficult, if not
impossible, to be adequately prepared for death if we
are reluctant to discuss it. If, as individuals, we seek
autonomy over our healthcare decisions, we must be
prepared to accept responsibility for the directives we
make in connection therewith.
Advance directives are often promoted as a
means for achieving patient autonomy (KassBartelmes, Hughes, & Rutherford, 2003). Yet,
research indicates that patients (and/or their
appointed healthcare surrogates) are not following
through with the directives contained therein. A
recent research study indicates that advance
directives are actually completed and signed by less
than 25% of most patient groups (Perkins, 2007).
Some of the reasons cited for not completing advance
directives were avoiding death related discussions,
lack of awareness, lack of understanding, and poor
support from healthcare personnel requesting
completion of the forms (Perkins, 2007).
It is important to note that, given the low
completion rates and other implementation
limitations, there remains considerable room for
improvement of the advance directive (Perkins,
2007). For example, one advance directive
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“implementation
problem
is
poor
proxy
representation” (Perkins, 2007, p. 53). The lack of
unambiguous, regular, or recent instructions between
the patient and proxy (i.e., family member or
designated significant other) may result in
overwhelming emotional anxiety and flawed
decision-making by the proxy (Perkins, 2007, p. 53).
This underscores the importance of family members
or significant others to reach out and initiate the endof-life discussion if it has not been initiated by the
patient.
Notwithstanding these limitations related to
advance directives process must be emphasized over
outcome. The process of discussing a patient’s
wishes and their options with a healthcare provider,
as well as their family, at early and regular intervals
can be immensely valuable in reducing potential
uncertainties among family members and healthcare
providers and, consequently, more closely aligning
end-of-life care decisions with a patient’s true
intentions.
Healthcare Provider Action
With respect to healthcare providers, two
potential areas for consideration arise: (1) improving
communication between the healthcare provider and
patient; and, (2) improving the delivery of palliativeoriented care.
Effective communication requires active
involvement by all relevant participants. Whereas we
have noted the value of a patient being willing to
discuss end-of-life matters with their healthcare
providers, it is of equal, if not greater importance, for
the healthcare provider to be a good listener and
advisor in this communication process. In evaluating
“what matters most” to patients during their end-oflife care, “having trust and confidence” in their
doctors was “most frequently rated as extremely
important” in a recently completed study of seriously
ill patients (Heyland, Dodek, Rocker, et al., 2006, p.
635).
Research suggests that a patient’s “trust and
satisfaction” levels may be dependent on their doctor
developing “relational closeness” with the patient
(Breen, Wan, Zhang, et al., 2008, p.159). To support
the healthcare provider in fostering this closer
relationship, addressing the nature of patient centered
dimensions of care may be helpful. As described by
the Picker Institute, based on more than 350,000
patient
survey
interviews,
patient-centered
dimensions of care include the following: “(1) respect
for the patient’s values, preferences, and expressed
needs; (2) access to care; (3) information and
education; (4) emotional support to relieve fear and
anxiety; (5) involvement of family and friends; (6)
continuity and secure transition between healthcare
settings; (7) physical comfort; and (8) coordination
Florida Public Health Review, 2010; 7:50-63.
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and integration of care” (Breen, Wan, Zhang, et al.,
2008, p. 156). The same study noted that almost four
of five physicians could potentially improve their
delivery of care by more effectively adopting
“patient-centric” dimensions of care (Breen, Wan,
Zhang, et al., 2008, p. 156). Another recent
quantitative study also found that “increasing
communication between patients and their physicians
is associated with better outcomes and with less
expensive medical care” (Zhang, Wright, Huskamp,
et al., 2009, p. 487).
Another area that warrants further consideration
among healthcare providers is palliative care. There
is an increasing amount of research based on the
perspective of patients and family members that
indicates a potential to improve the quality of the
end-of-life experience by greater consideration of
multi-disciplinary palliative care (Teno, et al., 2004;
Mitchell, 2002; Byock, Twohig, Merriman, et al.,
2006). Research also shows that the improved quality
of care can also be more cost effective (Byock, et al.,
2006). An Archives of Internal Medicine study
observed that when advanced cancer patients had
candid end-of-life discussions with their doctors they
experienced a reduction in acute care services and
there was an observed negative association between
quality of care and costs in the last week of life
(Zhang, et al., 2009).
“An expansion of palliative care programs in
hospitals” was one of the key policy
recommendations of a recent study that could
potentially result in lower healthcare costs while
concurrently improving the quality of end-of-life care
(Zhang, et al., 2009, p. 488). Whereas significant
progress has been made in the acceptance and
delivery of palliative care, the opportunity for
additional
improvement
remains
significant,
particularly in the areas of healthcare provider and
patient education, properly recognizing and
discussing the futility of care, and in the delivery of
coordinated palliative care in a multi-disciplinary
manner (Chwang, 2009; Meier, Morrison, & Cassel,
1997; Mahmood-Yousuf, Munday, King, et al.,
2008).
Government Action
Research suggests that a significant role exists
for government in improving end-of-life healthcare.
Effective policies and reform initiatives require an indepth understanding of current outcomes and costs.
There is a need to gather better healthcare utilization
and cost data on the experiences of end-of-life
patients (Wiener & Tilly, 2003). Improving
information technology within the healthcare system
offers the one potential means whereby to improve
quality of care, efficiency, and lower costs (Chugh,
2009).
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Whereas many advocate the expansion of the
Medicare hospice benefit and greater use of palliative
care services, additional evaluation may be needed on
quality of life indicators as well as the cost
effectiveness of palliative or hospice care. While
improving accessibility to palliative services
unequivocally provides greater choice and autonomy
for the patient, the cost effectiveness of such
programs remains unclear. Some studies, as stated
earlier, report significantly lower costs for patients
receiving palliative care while other studies have
concluded that the comparative costs for hospice
service were only marginally lower for cancer
patients and higher for non-cancer patients
(Campbell, Lynn, Louis, et al., 2004). This same
study concluded that “overall, hospice users incur an
estimated 4% greater [Medicare] costs than do
similar patients who do not use hospice” (Campbell,
Lynn, Louis, et al., 2004, p. 275). With respect to
addressing the final wishes of the patient, a recent
quality in end-of-life care study revealed that dying at
home was not as important to patients as not being a
burden to family (Heyland, Dodek, Rocker, et al.,
2006). Government can assume a significant role in
sponsoring greater research that is needed to better
understand patient and family preferences, quality
indicators of end-of-life care, and the relative cost
effectiveness of palliative care versus traditional
hospital services.
Another area that needs greater public policy
attention is expanding access to more effective pain
management. Research indicates that inadequate pain
management remains a significant problem during
end-of-life care (Imahof & Kaskie, 2008). A recent
study concluded that both federal and state polices
should be improved with respect to promoting more
effective pain management during end-of-life
(Imahof & Kaskie, 2008). Policy oriented pain
management studies indicate that the greatest
promise for effective policy reform in pain
management are likely to begin with initiatives at the
state level through the work of state attorney generals
and state medical boards (Imahof & Kaskie, 2008;
Edmondson, 2006). State attorneys general, in
particular, may be in the best position to improve
collaboration between “law enforcement and the
medical community about the balance between
effective pain management and the battle against
diversion of prescription drugs” (Edmondson, 2006,
p. 214).
Conclusions and Recommendations
Policy reform expectations for end-of-life care
stemming from reform of the American healthcare
system should be significantly moderated—there
appears to be plenty of lower hanging fruit when it
Florida Public Health Review, 2010; 7:50-63.
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comes to systematic healthcare reform. While there
may always be opportunities to improve the provision
of end-of-life care, this remains an intensely personal
issue. Many patients will experience a period of
chronic illness before their death. Some dying
patients may not lose hope until the very end,
whereas others may accept their fate sooner. Patients
deserve the autonomy to make these final end-of-life
healthcare choices in their own right, in consultation
with their families, and in consultation with their
physicians. There is no “one-size fits all” end-of-life
plan. Due to diverse medical and public opinions
surrounding this issue, it is unlikely that public policy
will be successful in finding a uniform, cost-efficient
approach to end-of-life healthcare. This limited role
for public policy suggests that healthcare providers
and patients, in the first instance, must assume
greater ownership and responsibility for end-of-life
planning. As citizens, healthcare providers, family
members, and future patients, we all should recognize
that we have a responsibility to become more
informed about end-of-life healthcare planning and to
take the necessary steps to ensure that the final
choices of patients are known and honored.
Addressing this need to improve patient and
healthcare provider awareness and accountability on
this issue may be one of the areas where we may be
best served in a non-intrusive, but supportive manner
by public policy. The end-of-life planning provision
in Section 1233 of H.R. 3200 may be a step in the
right direction by providing education regarding
advance directives and requiring periodic counseling
and providing provider reimbursement for these
services. It is unfortunate that the intention of the
provision was not properly communicated in the
midst of the heated debate surrounding healthcare
reform. It is our hope that, in the event the measure
does not mature into law, the issue be revisited again
when calmer minds prevail.
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